Browsing Tag
PARI Pharma GmbH
1 post
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Avalyn Pharma advances AP02 into Phase 2 trials, testing inhaled drug delivery as a safer IPF strategy. Discover what this means for the fibrosis market.